Cancer Care Ontario | Cancer Care Ontario

102 Results

Guidelines and Advice

Person-Centred Care Guideline

Status: Current
ID: GL-C50-20

May 2015

Guidelines and Advice

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Status: In-Review
ID: 3-22
Version: N/A

Apr 2020

Guidelines and Advice

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline

Status: Archived
ID: 6-8
Version: 3

Mar 2015

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2019

Status: Current
ID: PET 2019-2
Version: N/A

Jun 2020

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2020

Status: Current
ID: PET 2020-1
Version: N/A

Nov 2020

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2015

Status: Current
ID: PET 2015-1

Oct 2015

Guidelines and Advice

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2014

Status: Current
ID: PET 2014-2

Jun 2015

Guidelines and Advice

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Status: Current
ID: 7-A-2018-2
Version: N/A

Jan 2020

Guidelines and Advice

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

Status: Current
ID: GL #4-4v2
Version: 2

Sep 2020

Guidelines and Advice

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-18
Version: N/A

Sep 2020

Guidelines and Advice

Effective Use of Advanced Practice Nurses in the Delivery of Adult Cancer Services in Ontario

Status: In-Review
ID: 16-4

May 2015

Guidelines and Advice

Minimal Residual Disease Testing in Acute Leukemia

Status: Current
ID: MOTAC-6
Version: 2

Sep 2020

Person-Centred Care Guideline

An Endorsement of the 2018 Guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline

Rituximab in Lymphoma and Chronic Lymphocytic Leukemia: A Clinical Practice Guideline

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2019

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2020

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2015

PET Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2014

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Risk Reduction Strategies for BRCA1/2 Hereditary Ovarian Cancer Syndromes

Consolidation or maintenance systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Effective Use of Advanced Practice Nurses in the Delivery of Adult Cancer Services in Ontario

Minimal Residual Disease Testing in Acute Leukemia

Pages